Soricimed Biopharma Inc. has added a U.S. site to its Phase 1 clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The first patient will receive an anti-cancer agent known as SOR-C13 this week.
http://bionews-tx.com/news/2013/05/24/soricimed-biopharma-launches-phase-i-clinical-trial-of-new-cancer-drug-sor-c13-at-md-anderson/
No comments:
Post a Comment